View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
May 10, 2021updated 12 Jul 2022 11:18am

Endometrial cancer patients expected to benefit from novel advancements in the market

Endometrial cancer is a type of uterine cancer that is often diagnosed early and treated with surgery, chemotherapy or hormone therapy. Patients who present with advanced disease or who relapse after surgery have few options available, including chemotherapy, hormone therapy and off-label targeted therapies in the first line, with the addition of immunotherapy in the second line.

By GlobalData Healthcare

Endometrial cancer is a type of uterine cancer that is often diagnosed early and treated with surgery, chemotherapy or hormone therapy. Patients who present with advanced disease or who relapse after surgery have few options available, including chemotherapy, hormone therapy and off-label targeted therapies in the first line, with the addition of immunotherapy in the second line.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

There has historically been a lack of interest from drug developers to seek approvals for endometrial cancer. As a result, a significant amount of off-label drug use is recommended in the National Comprehensive Cancer Network (NCCN) guidelines. But recent advancements in the oncology market, specifically with biomarker testing and immunotherapy, have resulted in an increased interest in this market. GlobalData forecasts that these advancements will have a significant impact on the disease’s treatment paradigm, competitive landscape and attainment of unmet needs.

Endometrial cancer patients do not currently have a standardised biomarker testing routine, with only some hormone and human epidermal growth factor receptor 2 (HER-2) biomarker testing being performed. Due to the recent approval of Merck and Co’s Keytruda (pembrolizumab) in combination with Eisai’s Lenvima (lenvatinib), mismatch repair (MMR) and microsatellite instability (MSI) testing is also being performed.

The approval of this first immunotherapy in endometrial cancer has resulted in increased interest by other drug developers, reflected in the late-stage pipeline. Key opinion leaders (KOLs) interviewed by GlobalData believe that biomarkers will be significant in determining patient segmentation in endometrial cancer and will identify patient populations likely to benefit from novel therapies.

Supporting this expectation is the recent approval of Roche’s Ventana MMR RxDx panel. This is the first immunohistochemistry predictive test to be used as a companion test to GlaxoSmithKline’s Jemperli (dostarlimab), which received accelerated approval for monotherapy use by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). This panel, which determines a patient’s MMR status, is expected to introduce a new era of biomarker testing in endometrial cancer. Advanced and recurrent patients will now need to be segmented according to their MMR/MSI status to be eligible for the two approved therapies.

With the projected arrival of more pipeline agents, GlobalData expects that therapies will either fit into this patient segmentation or result in the development of further biomarkers to determine other segmentations. The Cancer Genome Atlas (TCGA) had previously determined four principal diagnostic groups in endometrial cancer patients, namely polymerase epsilon (POLE) mutated, MSI-high, copy number low (CNL) and copy number high (CNH). As novel therapies aim to gain approval for these groups, mostly based on MSI status, GlobalData anticipates that future drug developers will tailor clinical trials and seek specific approvals for the remaining diagnostic groups.

GlobalData projects that this will result overall in several unmet needs being met in endometrial cancer. This will both benefit current patients and create more market opportunities for new entrants, resulting in a greater patient population being served. In the future, it will become clearer which patients are well served by current and upcoming therapies and which patients still require novel therapies to be developed, thereby highlighting opportunities for drug stakeholders and promoting a novel competitive landscape in the endometrial cancer market.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena